Compare Cytokinetics Inc (CYTK) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Nasdaq100 ETF — how do they compare? Cytokinetics Inc trades at $62.66 (market cap $8.62B), while Nasdaq100 ETF trades at $750.43 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 58.8× Cytokinetics Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Nasdaq100 ETF for 162 Days on average.
| CYTK | QQQ | |
|---|---|---|
Market Cap | $8.62B | $506.92B |
Volume | 2,594,626 | 48,326,518 |
Sector | Health | — |
52-Week High | $87.26 | $759.66 |
52-Week Low | $54.76 | $558.34 |
Typical Hold Time | 19 Days | 162 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
QQQ trades at $749.24, down 1.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings and mixed analyst sentiment with a 50% buy/50% sell split. Recent news highlights QQQ's tech concentration and fee comparisons with competing ETFs, while broader market concerns about AI valuations and interest rates create headwinds.
The outlook remains cautiously optimistic given strong technical momentum, though elevated tech valuations and Federal Reserve policy pose risks. QQQ's innovation-focused portfolio offers growth exposure but requires monitoring of concentration risk in the technology sector amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
